The immunogenicity of melanoma is related to the expression of MART-1, gp100, TRP-1, TRP-2 and tyrosinase, which affects the behavior of tumor-infiltrating lymphocytes, CD4+ T and CD8+ T. It has been demonstrated that the high expression of melanoma markers, especially gp100 epitopes, correlates with tumor regression and could improve immunotherapy [38]. This evidence concerns the gene CD4 and neoplasm.